- Home
- BYSI vs AVTE Comparison
BYSI vs AVTE Comparison
Compare BYSI & AVTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- AVTE
- Stock Information
- Founded
- BYSI 2010
- AVTE 2018
- Country
- BYSI United States
- AVTE United States
- Employees
- BYSI N/A
- AVTE N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- AVTE Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- AVTE Health Care
- Exchange
- BYSI Nasdaq
- AVTE Nasdaq
- Market Cap
- BYSI 72.1M
- AVTE 72.5M
- IPO Year
- BYSI 2017
- AVTE 2021
- Fundamental
- Price
- BYSI $1.46
- AVTE $2.51
- Analyst Decision
- BYSI
- AVTE Hold
- Analyst Count
- BYSI 0
- AVTE 7
- Target Price
- BYSI N/A
- AVTE $11.75
- AVG Volume (30 Days)
- BYSI 14.1K
- AVTE 62.3K
- Earning Date
- BYSI 01-01-0001
- AVTE 03-27-2025
- Dividend Yield
- BYSI N/A
- AVTE N/A
- EPS Growth
- BYSI N/A
- AVTE N/A
- EPS
- BYSI N/A
- AVTE N/A
- Revenue
- BYSI N/A
- AVTE N/A
- Revenue This Year
- BYSI N/A
- AVTE N/A
- Revenue Next Year
- BYSI N/A
- AVTE N/A
- P/E Ratio
- BYSI N/A
- AVTE N/A
- Revenue Growth
- BYSI N/A
- AVTE N/A
- 52 Week Low
- BYSI $1.37
- AVTE $1.25
- 52 Week High
- BYSI $3.63
- AVTE $32.42
- Technical
- Relative Strength Index (RSI)
- BYSI 26.61
- AVTE 52.00
- Support Level
- BYSI $1.46
- AVTE $2.44
- Resistance Level
- BYSI $1.65
- AVTE $2.56
- Average True Range (ATR)
- BYSI 0.11
- AVTE 0.09
- MACD
- BYSI -0.03
- AVTE 0.00
- Stochastic Oscillator
- BYSI 2.13
- AVTE 77.14
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About AVTE Aerovate Therapeutics Inc.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.